Maven Securities LTD Lowers Position in OKYO Pharma Limited Sponsored ADR $OKYO

Maven Securities LTD cut its stake in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) by 31.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 809,317 shares of the company’s stock after selling 366,218 shares during the period. Maven Securities LTD owned about 1.54% of OKYO Pharma worth $1,214,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of OKYO. Citadel Advisors LLC purchased a new stake in shares of OKYO Pharma in the third quarter valued at about $31,000. XTX Topco Ltd purchased a new position in OKYO Pharma during the fourth quarter worth about $36,000. Finally, Renaissance Technologies LLC boosted its holdings in OKYO Pharma by 235.0% during the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after purchasing an additional 96,800 shares during the last quarter. 2.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on OKYO. HC Wainwright dropped their target price on shares of OKYO Pharma from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, July 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.67.

OKYO Pharma Trading Down 2.5%

NASDAQ OKYO opened at $1.53 on Wednesday. OKYO Pharma Limited Sponsored ADR has a one year low of $1.34 and a one year high of $3.20. The business’s fifty day moving average is $1.56 and its 200-day moving average is $1.60.

OKYO Pharma Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.